Three Questions Before the Big Bet

Fewer new drugs are entering pipelines, down 32% in the 2026 Pipeline-to-Patient Productivity Index, even as R&D spend is up 45%.

With fewer, larger bets on the table, every Phase 3 commitment, in-licensing deal and launch budget needs to be carefully assessed.

In this webinar, we look how real-world data can address three critical questions: who are the patients? What will win them? How much will the drug be used?

Share:

Watch now








About this webinar

Evaluate’s experts follow a hypothetical asset through a Phase 3 decision. Asset X is a targeted oncology therapy with encouraging Phase 2 data. The team must decide whether to go ahead and which patients to aim for.

The session traces how testing gaps and drop-off between lines of therapy shrink the population who could realistically receive the drug to just 22%. You will see what physician notes reveal about why patients switch or stop, and how that reshapes a target product profile.

The team will discuss:

  • Why counted patient numbers hold up better than estimated ones
  • What physician notes show about discontinuation, and how that should shape a target product profile
  • How to test a forecast against line of therapy, treatment pathways, payer mix and physician awareness
  • How probability of success and trial cost complete the case for a Phase 3 call

Our speakers bring hands-on experience from due diligence, target product profile development and forecasting work. You will leave with three questions to take back to your own assets and a clearer view of the evidence that can answer them.

Speakers

Ritu Yamujala

SVP, Consulting & Analytics

Ellie Davenport

Senior Solution Consultant
Carolyn Hall_Evaluate & Norstella

Carolyn Hall

Moderator

Frequently Asked Questions

It is Norstella’s benchmark of pharma productivity, built on Pharmapremia and Evaluate data. The webinar draws on its findings on pipeline entry, probability of success, launch performance and access.

A target product profile sets out what a drug needs to look like to succeed. The session shows how real-world evidence can test and sharpen one before a major commitment.

Insurance claims, electronic health records, physician notes and payer data, linked at the patient level so a patient can be followed from diagnosis through each line of therapy.

Three questions to test any asset: are your patient numbers counted or estimated, is your target product profile built on what changes prescribing, and is your forecast tested against what physicians do?

Explore all webinars